Plain-English translation of NCT05952661 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying a new approach to treating advanced esophageal squamous cell cancer that cannot be removed by surgery. Researchers want to see if measuring circulating tumor DNA (tiny fragments of cancer DNA floating in your blood) can help doctors understand how well your treatment is working and predict whether cancer might come back. You would receive standard chemotherapy and radiation combined with immunotherapy (a treatment that helps your immune system fight cancer), along with additional immunotherapy afterward.
Currently, doctors use imaging scans to check if cancer treatment is working, but these scans don't always catch cancer recurrence early enough. This trial tests whether blood tests for cancer DNA can detect treatment response and predict recurrence faster and more accurately than imaging alone, potentially helping doctors adjust your care plan sooner.
You likely qualify if…
You likely don't qualify if…
You would receive a sequence of treatments over several months: first, chemotherapy combined with immunotherapy before your main treatment; then radiation combined with chemotherapy and immunotherapy; and finally, additional immunotherapy afterward. Throughout this time, you would have blood draws and possibly tissue samples collected at multiple time points to measure cancer DNA levels. Researchers will use these measurements to track how your body is responding to treatment and to look for early signs of cancer recurrence.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China
Sponsor
Hebei Medical University Fourth Hospital
Enrollment target
~56 participants
Started
February 2023
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenbin Shen, PhD
Hebei Medical University Fourth Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.